Xilio Therapeutics shares are trading higher after the company announced an upcoming poster presentation entitled "Discovery and Optimization of XTX601, a Masked Claudin 18.2-Targeting T Cell Engager" at the American Association for Cancer Research annual meeting from April 17-22, 2026.